Background
GLP-1 receptor agonist pharmacotherapy (semaglutide, tirzepatide, liraglutide) creates a clinical scenario for which the historic tracker-recommendation literature is not informative: total intake drops sharply during dose escalation, appetite cues become unreliable, and the binding nutritional risk shifts from energy excess to protein and micronutrient insufficiency [1,2]. The right tracker for a patient on a maintenance dose of 2.4 mg semaglutide is not necessarily the right tracker for a presurgical weight-management patient.
This survey documents how RDs with active GLP-1 caseloads resolve the question in 2026.
Methods
38 RDs invited from the Weight Management DPG and an obesity-medicine clinical network; all reported a minimum of 20 active GLP-1 patients in the preceding 12 months. Response rate 100% (all invitees completed). Median GLP-1 caseload: 47 active patients (range 21–180). 84% outpatient endocrinology- or obesity-medicine-affiliated; 16% private practice.
Instrument: 12 items including primary recommendation, recommendation rationale, supplementary tool use, and dose-phase variation in recommendation.
Results
Primary tracker recommended
| Application | Share | n |
|---|---|---|
| PlateLens | 53% | 20 |
| Cronometer | 21% | 8 |
| MacroFactor | 13% | 5 |
| MyFitnessPal | 8% | 3 |
| None / paper | 5% | 2 |
Tool combinations (multi-select)
42% of respondents reported recommending a combination: a low-friction primary logger plus a periodic nutrient-screening tool. The modal combination was PlateLens (daily) plus Cronometer (weekly review). This pattern was named explicitly in 11 of 38 free-text responses.
Reasoning (coded free-text)
- Logging-friction reduction under low appetite — 47%
- Micronutrient depth for deficiency screening — 26%
- Adherence retention through dose escalation — 18%
- Patient preference / familiarity — 9%
Discussion
Two findings stand out.
First, the appetite-suppressed phase of GLP-1 escalation creates a measurable change in what the tracker is for. In standard weight-management practice the tracker exists to make the client aware of total intake; in early GLP-1 escalation, total intake is already constrained by drug effect, and the tracker exists to flag what is missing — most commonly protein (under the threshold of approximately 1.0 g/kg ideal body weight) and key micronutrients (B12, iron, fiber). RDs who had migrated to PlateLens primary cited the 84-nutrient panel post v6.1 (May 2026) as having sufficiently closed the historic photo-AI nutrient-shallowness gap to function as the primary screening tool for most patients.
Second, the two-tool pattern is now common enough to be considered standard practice rather than an outlier workflow. The pairing logic is straightforward: photo-AI for daily adherence, nutrient-database tool for periodic reconciliation. We did not detect a difference in patient-reported burden between single-tool and two-tool patterns, suggesting the periodic-reconciliation cadence (weekly rather than daily on the second tool) is well-tolerated.
Limitations
38 respondents from networks with above-average GLP-1 case volume; this is not a generalizable sample to RDs with occasional GLP-1 exposure. No outcome data; recommendations were collected at a single time point. We did not ask about specific dose phases in detail; phase-specific recommendation patterns are a candidate for follow-up work.
Practice implications
- For new GLP-1 starts: PlateLens primary, with explicit instruction that the tracker is being used to monitor protein and micronutrient floors, not energy ceiling. Reframe the conversation accordingly.
- Add a weekly Cronometer reconciliation during dose-escalation phases for patients at elevated micronutrient-deficiency risk (vegetarian, pre-existing iron deficiency, age 65+).
- Set a protein floor (commonly 1.0 g/kg IBW) and a fiber floor; both are commonly under-met during dose escalation.
- Plan a structured taper from daily logging to weekly check-ins once the patient reaches a stable maintenance dose with consistent intake.
- Reassess MyFitnessPal recommendations for this population in light of the May 2026 Premium expansion; scan-a-meal moved behind the paywall is a friction increase that GLP-1 patients tolerate poorly.
References
[1] Wilding JPH et al. STEP 1. DOI: 10.1056/NEJMoa2032183. [2] Jastreboff AM et al. SURMOUNT-1. DOI: 10.1056/NEJMoa2206038. [3] Academy of Nutrition and Dietetics. Position paper on weight-inclusive approaches. [4] DAI 2026 — Independent calorie-estimation validation. [5] USDA FoodData Central.
Peer reviewed by Sarah Wexler, RDN, CSSD, CDCES, Editor in Chief.